DTIL insider trading
NasdaqCM HealthcarePRECISION BIOSCIENCES INC: insider trade history from SEC Form 4 filings.
About PRECISION BIOSCIENCES INC
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Company website: precisionbiosciences.com
DTIL insider activity at a glance
FilingIQ tracks 276 insider transactions for DTIL in filings since Apr 1, 2019. The most recent transaction is dated Sep 28, 2026.
Across the full history, 29 open-market purchases
and 80 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DTIL insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DTIL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DTIL?
- FilingIQ tracks 276 Form 4 insider transactions for DTIL (PRECISION BIOSCIENCES INC), covering filings from Apr 1, 2019 onwards. 3 of those are dated within the last 90 days.
- Are DTIL insiders net buyers or net sellers?
- Across the full Form 4 history for DTIL, 29 transactions (11%) were open-market purchases and 80 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DTIL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is DTIL in?
- PRECISION BIOSCIENCES INC (DTIL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $93.52M.
Methodology & sources
Every DTIL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.